U.S. markets open in 4 hours 10 minutes
  • S&P Futures

    3,830.50
    +2.50 (+0.07%)
     
  • Dow Futures

    31,343.00
    -28.00 (-0.09%)
     
  • Nasdaq Futures

    12,817.00
    -14.75 (-0.11%)
     
  • Russell 2000 Futures

    2,192.30
    -7.70 (-0.35%)
     
  • Crude Oil

    62.87
    -0.66 (-1.04%)
     
  • Gold

    1,761.20
    -14.20 (-0.80%)
     
  • Silver

    26.90
    -0.78 (-2.84%)
     
  • EUR/USD

    1.2127
    -0.0059 (-0.49%)
     
  • 10-Yr Bond

    1.5180
    0.0000 (0.00%)
     
  • Vix

    28.12
    +6.78 (+31.77%)
     
  • GBP/USD

    1.3930
    -0.0082 (-0.59%)
     
  • USD/JPY

    106.4120
    +0.1820 (+0.17%)
     
  • BTC-USD

    46,396.79
    -3,000.74 (-6.07%)
     
  • CMC Crypto 200

    926.73
    -6.40 (-0.69%)
     
  • FTSE 100

    6,620.87
    -31.09 (-0.47%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that second quarter 2019 financial results will be reported on Thursday, August 8, 2019. The company will host a webcast and conference call at 8:00 a.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international) and entering the conference code: 1986563. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics based upon the Company’s proprietary PRINT® particle engineering platform. The Company is currently conducting a Phase 3 clinical trial (INSPIRE) of LIQ861, a formulation of treprostinil for delivery via a dry powder inhaler, for the treatment of pulmonary arterial hypertension (PAH). Additionally, the Company has completed two Phase 1 clinical trials for LIQ865, a sustained release formulation of bupivacaine, a non-opioid anesthetic, for the treatment of local post-operative pain through a single injection. For more information please visit the Company’s website at www.liquidia.com.

Contact Information

Investors:
Jason Adair
Vice President, Corporate Development & Strategy
919.328.4350
IR@liquidia.com

Media:
Christy Curran
Sam Brown Inc.
615.414.8668
media@liquidia.com